Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy

Roodman, 2010, Pathogenesis of myeloma bone disease, J Cell Biochem., 109, 283, 10.1002/jcb.22403

Toscani, 2016, The Proteasome inhibitor Bortezomib maintains Osteocyte viability in multiple myeloma patients by reducing both apoptosis and autophagy: a new function for proteasome inhibitors, J Bone Miner Res., 31, 815, 10.1002/jbmr.2741

Giuliani, 2012, Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation, Leukemia, 26, 1391, 10.1038/leu.2011.381

Sapir-Koren, 2014, Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?, Osteoporos Int., 25, 2685, 10.1007/s00198-014-2808-0

Delgado-Calle, 2016, Bidirectional notch signaling and Osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma, Cancer Res., 76, 1089, 10.1158/0008-5472.CAN-15-1703

McDonald, 2017, Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma, Blood, 129, 3452, 10.1182/blood-2017-03-773341

Terpos, 2012, Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy, Int J Cancer, 131, 1466, 10.1002/ijc.27342

Delgado-Calle, 2017, Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth, Leukemia, 31, 2686, 10.1038/leu.2017.152

Ominsky, 2017, Effects of sclerostin antibodies in animal models of osteoporosis, Bone, 96, 63, 10.1016/j.bone.2016.10.019

Recker, 2015, A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density, J Bone Miner Res., 30, 216, 10.1002/jbmr.2351

Cosman, 2016, Romosozumab treatment in Postmenopausal women with osteoporosis, N Engl J Med., 375, 1532, 10.1056/NEJMoa1607948

Palumbo, 1990, Osteocyte differentiation in the tibia of newborn rabbit: an ultrastructural study of the formation of cytoplasmic processes, Acta Anat., 137, 350, 10.1159/000146907

Buenzli, 2015, Quantifying the osteocyte network in the human skeleton, Bone, 75, 144, 10.1016/j.bone.2015.02.016

Palumbo, 1990, Morphological study of intercellular junctions during osteocyte differentiation, Bone, 11, 401, 10.1016/8756-3282(90)90134-K

Palazzini, 1998, Stromal cell structure and relationships in perimedullary spaces of chick embryo shaft bones, Anat Embryol., 197, 349, 10.1007/s004290050145

Marotti, 2000, The osteocyte as a wiring transmission system, J Musculoskelet Neuronal Interact., 1, 133

Kenkre, 2018, The bone remodelling cycle, Ann Clin Biochem., 55, 308, 10.1177/0004563218759371

Bonewald, 2011, The amazing osteocyte, J Bone Miner Res., 26, 229, 10.1002/jbmr.320

Matsuo, 2012, Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases, Cell Adh Migr., 6, 148, 10.4161/cam.20888

Baron, 2013, WNT signaling in bone homeostasis and disease: from human mutations to treatments, Nat Med., 19, 179, 10.1038/nm.3074

Dallas, 2013, The osteocyte: an endocrine cell… and more, Endocr Revi., 34, 658, 10.1210/er.2012-1026

Delaisse, 2014, The reversal phase of the bone-remodeling cycle: cellular prerequisites for coupling resorption and formation, Bonekey Rep., 3, 561, 10.1038/bonekey.2014.56

Lanske, 2014, Vitamin D endocrine system and osteocytes, Bonekey Rep., 3, 494, 10.1038/bonekey.2013.228

Sims, 2014, Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit, Bonekey Rep., 3, 481, 10.1038/bonekey.2013.215

Goldring, 2015, The osteocyte: key player in regulating bone turnover, RMD Open, 1, e000049, 10.1136/rmdopen-2015-000049

Sims, 2015, Coupling signals between the Osteoclast and Osteoblast: how are messages transmitted between these temporary visitors to the bone surface?, Front. Endocrinol., 6, 41, 10.3389/fendo.2015.00041

Xiong, 2015, Osteocytes, not Osteoblasts or lining cells, are the main source of the RANKL required for Osteoclast formation in remodeling bone, PLoS ONE, 10, e0138189, 10.1371/journal.pone.0138189

Bassett, 2016, Role of Thyroid hormones in skeletal development and bone maintenance, Endocr Rev., 37, 135, 10.1210/er.2015-1106

Prideaux, 2016, Osteocytes: the master cells in bone remodelling, Curr Opin Pharmacol., 28, 24, 10.1016/j.coph.2016.02.003

Palumbo, 2001, Osteocyte-osteoclast morphological relationships and the putative role of osteocytes in bone remodeling, J Musculoskelet Neuronal Interact., 1, 327

Burr, 2002, Targeted and nontargeted remodeling, Bone, 30, 2, 10.1016/S8756-3282(01)00619-6

Parfitt, 2002, Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression, Bone, 30, 5, 10.1016/S8756-3282(01)00642-1

Atkins, 2012, Osteocyte regulation of bone mineral: a little give and take, Osteoporos Int., 23, 2067, 10.1007/s00198-012-1915-z

Tatsumi, 2007, Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction, Cell Metab., 5, 464, 10.1016/j.cmet.2007.05.001

Chen, 2015, The osteocyte plays multiple roles in bone remodeling and mineral homeostasis, Med Mol Morphol., 48, 61, 10.1007/s00795-015-0099-y

Noble, 2003, Mechanical loading: biphasic osteocyte survival and targeting of osteoclasts for bone destruction in rat cortical bone, Am J Physiol Cell Physiol., 284, C934, 10.1152/ajpcell.00234.2002

Kogianni, 2008, Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localized bone destruction, J Bone Miner Res., 23, 915, 10.1359/jbmr.080207

Capulli, 2014, Osteoblast and osteocyte: games without frontiers, Arch Biochem Biophys., 561, 3, 10.1016/j.abb.2014.05.003

Bonewald, 2006, Osteocytes as multifunctional cells, J Musculoskelet Neuronal Interact., 6, 331

Bonewald, 2006, Mechanosensation and transduction in osteocytes, Bonekey Osteovision, 3, 7, 10.1138/20060233

Bonewald, 2008, Osteocytes, mechanosensing and Wnt signaling, Bone, 42, 606, 10.1016/j.bone.2007.12.224

Lau, 2010, Effect of low-magnitude, high-frequency vibration on osteocytes in the regulation of osteoclasts, Bone, 46, 1508, 10.1016/j.bone.2010.02.031

Rochefort, 2010, Osteocyte: the unrecognized side of bone tissue, Osteoporos Int., 21, 1457, 10.1007/s00198-010-1194-5

Iolascon, 2013, Mechanobiology of bone, Aging Clin Exp Res., 25, S3, 10.1007/s40520-013-0101-2

Rubinacci, 1998, Osteocyte-bone lining cell system at the origin of steady ionic current in damaged amphibian bone, Calcif Tissue Int., 63, 331, 10.1007/s002239900536

Nakashima, 2011, Evidence for osteocyte regulation of bone homeostasis through RANKL expression, Nat Med., 17, 1231, 10.1038/nm.2452

Amarasekara, 2018, Regulation of Osteoclast differentiation by cytokine networks, Immune Netw., 18, e8, 10.4110/in.2018.18.e8

Luo, 2018, TNFalpha and RANKL promote osteoclastogenesis by upregulating RANK via the NFkappaB pathway, Mol Med Rep., 17, 6605, 10.3892/mmr.2018.8698

Everts, 2002, The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation, J Bone Miner Res., 17, 77, 10.1359/jbmr.2002.17.1.77

Raggatt, 2010, Cellular and molecular mechanisms of bone remodeling, J Biol Chem., 285, 25103, 10.1074/jbc.R109.041087

Zhao, 2006, Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis, Cell Metab., 4, 111, 10.1016/j.cmet.2006.05.012

Clevers, 2012, Wnt/beta-catenin signaling and disease, Cell, 149, 1192, 10.1016/j.cell.2012.05.012

Williams, 2014, Insights into the mechanisms of sclerostin action in regulating bone mass accrual, J Bone Miner Res., 29, 24, 10.1002/jbmr.2154

Delgado-Calle, 2012, DNA methylation contributes to the regulation of sclerostin expression in human osteocytes, J Bone Miner Res., 27, 926, 10.1002/jbmr.1491

Feng, 2006, Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism, Nat Genet., 38, 1310, 10.1038/ng1905

Sapir-Koren, 2011, Bone mineralization and regulation of phosphate homeostasis, IBMS BoneKEy, 8, 286, 10.1138/20110516

van Bezooijen, 2009, Sclerostin in mineralized matrices and van Buchem disease, J Dent Res., 88, 569, 10.1177/0022034509338340

Li, 2005, Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling, J Biol Chem., 280, 19883, 10.1074/jbc.M413274200

Krishnan, 2006, Regulation of bone mass by Wnt signaling, J Clin Invest., 116, 1202, 10.1172/JCI28551

You, 2008, Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading, Bone, 42, 172, 10.1016/j.bone.2007.09.047

Wijenayaka, 2011, Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway, PLoS ONE, 6, e25900, 10.1371/journal.pone.0025900

Honma, 2013, RANKL subcellular trafficking and regulatory mechanisms in osteocytes, J Bone Miner Res., 28, 1936, 10.1002/jbmr.1941

Li, 2009, Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis, J Bone Miner Res., 24, 578, 10.1359/jbmr.081206

Veverka, 2009, Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation, J Biol Chem., 284, 10890, 10.1074/jbc.M807994200

Ominsky, 2010, Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength, J Bone Miner Res., 25, 948, 10.1002/jbmr.14

Ominsky, 2014, Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody, J Bone Miner Res., 29, 1424, 10.1002/jbmr.2152

Taylor, 2016, Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats, Bone, 84, 148, 10.1016/j.bone.2015.12.013

Nioi, 2015, Transcriptional profiling of laser capture microdissected subpopulations of the osteoblast lineage provides insight into the early response to Sclerostin antibody in rats, J Bone Miner Res., 30, 1457, 10.1002/jbmr.2482

Li, 2014, Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody, Endocrinology, 155, 4785, 10.1210/en.2013-1905

Florio, 2016, A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair, Nat Commun., 7, 11505, 10.1038/ncomms11505

Padhi, 2011, Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody, J Bone Miner Res., 26, 19, 10.1002/jbmr.173

Graeff, 2015, Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis, Bone, 81, 364, 10.1016/j.bone.2015.07.036

McClung, 2014, Romosozumab in postmenopausal women with low bone mineral density, N Engl J Med., 370, 412, 10.1056/NEJMoa1305224

Saag, 2017, Romosozumab or Alendronate for fracture prevention in women with osteoporosis, N Engl J Med., 377, 1417, 10.1056/NEJMoa1708322

Glorieux, 2017, BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial, J Bone Miner Res., 32, 1496, 10.1002/jbmr.3143

Morse, 2014, Mechanical load increases in bone formation via a sclerostin-independent pathway, J Bone Miner Res., 29, 2456, 10.1002/jbmr.2278

van Lierop, 2014, Serum Dickkopf 1 levels in sclerostin deficiency, J Clin Endocrinol Metab., 99, E252, 10.1210/jc.2013-3278

Recknor, 2015, The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density, J Bone Miner Res., 30, 1717, 10.1002/jbmr.2489

Palumbo, 2011, Multiple myeloma, N Engl J Med., 364, 1046, 10.1056/NEJMra1011442

Roodman, 2009, Pathogenesis of myeloma bone disease, Leukemia, 23, 435, 10.1038/leu.2008.336

Yaccoby, 2010, Advances in the understanding of myeloma bone disease and tumour growth, Br J Haematol., 149, 311, 10.1111/j.1365-2141.2010.08141.x

Kyle, 2003, Review of 1027 patients with newly diagnosed multiple myeloma, Mayo Clin Proc., 78, 21, 10.4065/78.1.21

Lee, 2017, Bisphosphonate guidelines for treatment and prevention of myeloma bone disease, Intern Med J., 47, 938, 10.1111/imj.13502

Choi, 2000, Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma, Blood, 96, 671, 10.1182/blood.V96.2.671

Kitaura, 2004, Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo, J Immunol., 173, 4838, 10.4049/jimmunol.173.8.4838

Lee, 2004, IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells, Blood, 103, 2308, 10.1182/blood-2003-06-1992

Giuliani, 2005, Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation, Blood, 106, 2472, 10.1182/blood-2004-12-4986

Giuliani, 2006, Multiple myeloma bone disease: pathophysiology of osteoblast inhibition, Blood, 108, 3992, 10.1182/blood-2006-05-026112

Toscani, 2015, The osteoblastic niche in the context of multiple myeloma, Ann N Y Acad Sci., 1335, 45, 10.1111/nyas.12578

Ehrlich, 2005, IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma, Blood, 106, 1407, 10.1182/blood-2005-03-1080

Vallet, 2010, Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease, Proc Natl Acad Sci USA., 107, 5124, 10.1073/pnas.0911929107

Oshima, 2005, Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2, Blood, 106, 3160, 10.1182/blood-2004-12-4940

Giuliani, 2007, Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment, Cancer Res., 67, 7665, 10.1158/0008-5472.CAN-06-4666

Palma, 2016, Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20, Leukemia, 30, 409, 10.1038/leu.2015.259

Eisenberger, 2008, Metastases and multiple myeloma generate distinct transcriptional footprints in osteocytes in vivo, J Pathol., 214, 617, 10.1002/path.2322

Gatti, 2012, Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin, Bone, 50, 739, 10.1016/j.bone.2011.11.028

Keller, 2005, SOST is a target gene for PTH in bone, Bone, 37, 148, 10.1016/j.bone.2005.03.018

O'Brien, 2008, Control of bone mass and remodeling by PTH receptor signaling in osteocytes, PLoS ONE, 3, e2942, 10.1371/journal.pone.0002942

Wang, 2014, Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics, Leuk Res., 38, 525, 10.1016/j.leukres.2014.02.010

Colucci, 2011, Myeloma cells suppress osteoblasts through sclerostin secretion, Blood Cancer J., 1, e27, 10.1038/bcj.2011.22

Eda, 2016, Regulation of Sclerostin expression in multiple myeloma by Dkk-1: a potential therapeutic strategy for myeloma bone disease, J Bone Miner Res., 31, 1225, 10.1002/jbmr.2789

Chamorro, 2005, FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development, EMBO J., 24, 73, 10.1038/sj.emboj.7600460